| 1 |
Rafique A, Sharmin S, Raj A, et al. Comparative overview of Aspergillus fumigatus, A. flavus, and A. niger: pathogenicity, resistance, and public health significance[J]. J Infect Public Health, 2026, 19(2): 103070.
|
| 2 |
张丽, 康梅, 陈中举, 等. 我国霉菌感染流行病学分析: 多中心回顾性研究[J]. 协和医学杂志, 2023, 14(3): 559-565.
|
| 3 |
Sedik S, Wolfgruber S, Hoenigl M, et al. Diagnosing fungal infections in clinical practice: a narrative review[J]. Expert Rev Anti Infect Ther, 2024, 22(11): 935-949.
|
| 4 |
Prattes J, Giacobbe DR, Marelli C, et al. Posaconazole for prevention of COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a European multicentre case-control study (POSACOVID)[J]. Mycoses, 2025, 68(1): e70023.
|
| 5 |
Cao Y, Li Y, Wang M, et al. Epidemiological shifts and advances in research on early diagnosis of invasive fungal infection in critically ill patients[J]. Front Cell Infect Microbiol, 2025, 15: 1658476.
|
| 6 |
van Rhijn N, Rhodes J. Evolution of antifungal resistance in the environment[J]. Nat Microbiol, 2025, 10(8): 1804-1815.
|
| 7 |
Pfaller MA, Carvalhaes CG, Castanheira M. Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity[J]. Mycoses, 2023, 66(10): 854-868.
|
| 8 |
徐媛, 陈敏, 廖万清. 中国侵袭性曲霉菌病流行病学现状[J]. 中国真菌学杂志, 2018, 13(1): 57-60.
|
| 9 |
Krifors A, Blennow O, Påhlman LI, et al. Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden: a prospective multicentre cohort study[J]. Infect Dis (Lond), 2024, 56(2): 110-115.
|
| 10 |
Xia LJ, Hou TT, Liu XL, et al. Impact of physician awareness and microbiological examination on incidence of COVID-19-associated pulmonary aspergillosis: a retrospective study[J]. BMC Pulm Med, 2025, 25(1): 198.
|
| 11 |
Feys S, Carvalho A, Clancy CJ, et al. Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients[J].Lancet Respir Med, 2024, 12(9): 728-742.
|
| 12 |
Denning DW. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024, 24(7): e428-e438.
|
| 13 |
Mahalaxmi I, Jayaramayya K, Venkatesan D, et al. Mucormycosis: an opportunistic pathogen during COVID-19[J]. Environ Res, 2021, 201: 111643.
|
| 14 |
Feys S, Lagrou K, Lauwers HM, et al. High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation[J]. Clin Infect Dis, 2024, 78(2): 361-370.
|
| 15 |
Kontoyiannis DP, Walsh TJ. Mucormycosis[J]. N Engl J Med, 2026, 394(7): 684-698.
|
| 16 |
Demonchy J, Biard L, Clere-Jehl R, et al. Multicenter retrospective study of invasive Fusariosis in Intensive Care Units, France[J]. Emerg Infect Dis, 2024, 30(2): 215-224.
|
| 17 |
Sheng M, Ritchie B, Afshari Mirak S, et al. Review of Fusariosis in patients with hematologic malignancies[J]. Radiol Imaging Cancer, 2025, 7(6): e250174.
|
| 18 |
潘月秋, 黄昉芳, 卫建华, 等. 1例心脏移植术后并发下肢侵袭性镰刀菌感染患者的护理[J]. 中华护理杂志, 2025, 60(22): 2762-2766.
|
| 19 |
Nucci M, Anaissie E. Invasive fusariosis[J]. Clin Microbiol Rev, 2023, 36(4): e0015922.
|
| 20 |
Pérez-Nadales E, Alastruey-Izquierdo A, Linares-Sicilia MJ, et al. Invasive Fusariosis in nonneutropenic patients, Spain, 2000-2015[J]. Emerg Infect Dis, 2021, 27(1): 26-35.
|
| 21 |
Agrawal R, Yeldandi A, Savas H, et al. Pulmonary Mucormycosis: risk factors, radiologic findings, and pathologic correlation[J]. Radiographics, 2020, 40(3): 656-666.
|
| 22 |
Janssens I, Lambrecht BN, Van Braeckel E. Aspergillus and the lung[J]. Semin Respir Crit Care Med, 2024, 45(1): 3-20.
|
| 23 |
He H, Ding L, Li F, et al. Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study[J]. Crit Care, 2011, 15(1): R5.
|
| 24 |
Desai SM, Gujarathi-Saraf A, Agarwal EA. Imaging findings using a combined MRI/CT protocol to identify the "entire iceberg" in post-COVID-19 mucormycosis presenting clinically as only "the tip"[J]. Clin Radiol, 2021, 76(10): 784.e27-784.e33.
|
| 25 |
Ghuman SS, Sindhu P, Buxi T, et al. CT appearance of gastrointestinal tract mucormycosis[J]. Abdom Radiol (NY), 2021, 46(5): 1837-1845.
|
| 26 |
Marom EM, Holmes AM, Bruzzi JF, et al. Imaging of pulmonary Fusariosis in patients with hematologic malignancies[J]. AJR Am J Roentgenol, 2008, 190(6): 1605-1609.
|
| 27 |
Middlebrooks EH, Frost CJ, De Jesus RO, et al. Acute invasive fungal rhinosinusitis: a comprehensive update of CT findings and design of an effective diagnostic imaging model[J]. AJNR Am J Neuroradiol, 2015, 36(8): 1529-1535.
|
| 28 |
Erami M, Aboutalebian S, Hashemi Hezaveh SJ, et al. Invasive Fusarium rhinosinusitis in COVID-19 patients: report of three cases with successful management[J]. Front Cell Infect Microbiol, 2023, 13: 1247491.
|
| 29 |
张英芳, 黄琳娜, 詹庆元, 等. 重症监护室中侵袭性肺曲霉菌病的诊断标准: 因人而异[J]. 内科急危重症杂志, 2022, 28(5): 361-367.
|
| 30 |
Bassetti M, Azoulay E, Kullberg BJ, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the Intensive Care Unit Working Group[J]. Clin Infect Dis, 2021, 72(Suppl 2): S121-S127.
|
| 31 |
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of Mucormycosis: an update[J]. J Fungi (Basel), 2020, 6(4): 265.
|
| 32 |
中华人民共和国国家卫生健康委员会. 侵袭性真菌病实验诊断标准[EB/OL]. (2026-04-30) [2026-05-25].
|
| 33 |
Alam F, Siddiqui B, Hasan N, et al. Rapid cytological diagnosis with evaluation of pre- and post-therapeutic fungal morphological characteristics in Mucormycosis[J]. J Clin Med Res, 2023, 15(1): 31-37.
|
| 34 |
Yang J, Wu X, Zhang Q, et al. Metagenomic next-generation sequencing and galactomannan testing for the diagnosis of invasive pulmonary aspergillosis[J]. Sci Rep, 2024, 14(1): 31389.
|
| 35 |
Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together[J]. Curr Opin Crit Care, 2019, 25(5): 430-437.
|
| 36 |
中华医学会检验医学分会临床微生物学组. 侵袭性真菌病实验室诊断指南[J]. 中华检验医学杂志, 2022, 45(2): 119-126.
|
| 37 |
Tsotsolis S, Kotoulas SC, Lavrentieva A. Invasive pulmonary aspergillosis in coronavirus disease 2019 patients lights and shadows in the current landscape[J]. Adv Respir Med, 2023, 91(3): 185-202.
|
| 38 |
Tuon FF. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples[J]. Rev Iberoam Micol, 2007, 24(2): 89-94.
|
| 39 |
Sun W, Wang K, Gao W, et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate Meta-analysis and systematic review[J]. PLoS One, 2011, 6(12): e28467.
|
| 40 |
Lamoth F, Kontoyiannis DP. PCR diagnostic platforms for non-Aspergillus mold infections: ready for routine implementation in the clinic?[J]. Expert Rev Mol Diagn, 2024, 24(4): 273-282.
|
| 41 |
Liu X, Song Y, Li R. The use of combined PCR, fluorescence in situ hybridisation and immunohistochemical staining to diagnose mucormycosis from formalin-fixed paraffin-embedded tissues[J]. Mycoses, 2021, 64(12): 1460-1470.
|
| 42 |
Gholinejad-Ghadi N, Shokohi T, Seifi Z, et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples[J]. Mycoses, 2018, 61(12): 909-915.
|
| 43 |
Han Y, Wu X, Jiang G, et al. Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnostic meta-analysis[J]. BMC Pulm Med, 2023, 23(1): 58.
|
| 44 |
Lamoth F, Akan H, Andes D, et al. Assessment of the Role of 1, 3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults[J]. Clin Infect Dis, 2021, 72(Suppl 2): S102-S108.
|
| 45 |
郭景景, 李钦峰, 吴海华, 等.(1, 3)-β-D葡聚糖、半乳甘露聚糖联合降钙素原检测对侵袭性真菌感染的诊断价值[J].国际免疫学杂志, 2020, 43(1): 31-36.
|
| 46 |
Egger M, Prüller F, Krause R, et al. Utility of serum 1, 3-β-d-glucan testing for diagnosis and prognostication in COVID-19-associated pulmonary aspergillosis[J]. Microbiol Spectr, 2022, 10(3): e0137322.
|
| 47 |
Huang QY, Li PC, Yue JR. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis[J]. Medicine (Baltimore), 2024, 103(5): e37067.
|
| 48 |
Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis[J]. PLoS One, 2012, 7(8): e43347.
|
| 49 |
Çuhadar T, Kalkancı A, Tunçcan GÖ, et al. Comparison of the results of galactomannan and beta glucan antigen tests in the suspicion of invasive pulmonary aspergillosis[J]. Mikrobiyol Bul, 2023, 57(2): 274-282.
|
| 50 |
Komorowski AS, Hall CW, Atwal S, et al. Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis[J]. Clin Microbiol Infect, 2024, 30(10): 1244-1253.
|
| 51 |
Vanderbeke L, Jacobs C, Feys S, et al. A pathology-based case series of influenza- and COVID-19-associated Pulmonary aspergillosis: the proof is in the tissue[J]. Am J Respir Crit Care Med, 2023, 208(3): 301-311.
|
| 52 |
Naik S, Kashyap D, Deep J, et al. Utilizing next-generation sequencing: advancements in the diagnosis of fungal infections[J]. Diagnostics (Basel), 2024, 14(15): 1664.
|
| 53 |
Rodino KG, Simner PJ. Status check: next-generation sequencing for infectious-disease diagnostics[J]. J Clin Invest, 2024, 134(4): e178003.
|
| 54 |
Niu S, Liu D, Yang Y, et al. Clinical utility of metagenomic next-generation sequencing in the diagnosis of invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease patients in the intensive care unit[J]. Front Cell Infect Microbiol, 2024, 14: 1397733.
|
| 55 |
Diao Z, Zhang Y, Chen Y, et al. Assessing the quality of metagenomic next-generation sequencing for pathogen detection in lower respiratory infections[J]. Clin Chem, 2023, 69(9): 1038-1049.
|
| 56 |
Liu Z, Chen H, Chen D, et al. Metagenomic next-generation sequencing for the diagnosis of invasive pulmonary aspergillosis in type 2 diabetes mellitus patients[J]. Sci Rep, 2024, 14(1): 16618.
|
| 57 |
Xu CH, Zhang LN, Liu T, et al. Performance of Galactomannan, Aspergillus-PCR, and metagenomic sequencing for the diagnosis of invasive pulmonary aspergillosis in hematological patients[J]. J Microbiol Immunol Infect, 2025, 58(6): 743-750.
|
| 58 |
Han D, Diao Z, Lai H, et al. Multilaboratory assessment of metagenomic next-generation sequencing for unbiased microbe detection[J]. J Adv Res, 2022, 38: 213-222.
|
| 59 |
Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials[J]. Crit Care Med, 2006, 34(4): 1216-1224.
|
| 60 |
Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients[J]. Cochrane Database Syst Rev, 2016, 2016(1): CD004920.
|
| 61 |
Bartalucci C, Mezzogori L, Schiavoni R, et al. Antifungal treatment strategies in intensive care unit patients[J]. Eur J Clin Invest, 2026, 56(1): e70177.
|
| 62 |
Hatzl S, Reisinger AC, Posch F, et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study[J]. Crit Care, 2021, 25(1): 335.
|
| 63 |
Sprute R, Nacov JA, Neofytos D, et al. Antifungal prophylaxis and pre-emptive therapy: when and how?[J]. Mol Aspects Med, 2023, 92: 101190.
|
| 64 |
Hosseini-Moghaddam SM, Chaparro C, Luong ML, et al. The effectiveness of culture-directed preemptive anti-Aspergillus treatment in lung transplant recipients at one year after transplant[J]. Transplantation, 2015, 99(11): 2387-2393.
|
| 65 |
Chang A, Musk M, Lavender M, et al. Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia[J]. Transpl Infect Dis, 2019, 21(3): e13085.
|
| 66 |
Baker AW, Maziarz EK, Arnold CJ, et al. Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis[J]. Clin Infect Dis, 2020, 70(1): 30-39.
|
| 67 |
Pennington KM, Dykhoff HJ, Yao X, et al. The impact of antifungal prophylaxis in lung transplant recipients[J]. Ann Am Thorac Soc, 2021, 18(3): 468-476.
|
| 68 |
Hunter CJ, Chou A, Roeder H, et al. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia[J]. Leuk Res, 2026, 160: 108144.
|
| 69 |
Ju C, Lian Q, Wang X, et al. Efficacy of different durations of antifungal prophylaxis with nebulized amphotericin B after lung transplantation: a retrospective cohort study[J]. J Thorac Dis, 2023, 15(10): 5396-5404.
|
| 70 |
Wang Y, Xie J, Xing Y, et al. Choosing optimal antifungal agents to prevent fungal infections in nonneutropenic critically ill patients: trial sequential analysis, network Meta-analysis, and pharmacoeconomic analysis[J]. Antimicrob Agents Chemother, 2017, 61(12): e00620-17.
|
| 71 |
Albakri SA, Aljabri AK, Alharbi EA, et al. Effectiveness and safety of empirical antifungal strategies in critically ill, non-neutropenic patients: a multi-center observational study[J]. Infect Drug Resist, 2026, 19: 579631.
|
| 72 |
Chen Y, Zhao J, Wang Y, et al. The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review[J]. Front Pharmacol, 2025, 15: 1530999.
|
| 73 |
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial[J]. Lancet, 2016, 387(10020): 760-769.
|
| 74 |
Liu A, Xiong L, Wang L, et al. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis[J]. BMC Infect Dis, 2024, 24(1): 581.
|
| 75 |
Gu Q, Chen Y, Ding P, et al. Antifungal treatment regimens as primary therapy for invasive aspergillosis: a systematic review and network Meta-analysis[J]. Drugs, 2026, 86(6): 927-941.
|
| 76 |
张婷婷, 孙玲洁, 冯四洲, 等. 艾沙康唑治疗侵袭性真菌病的临床研究进展[J].中国感染与化疗杂志, 2022, 22(3): 360-365.
|
| 77 |
Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial[J]. Ann Intern Med, 2015, 162(2): 81-89.
|
| 78 |
McCarthy MW, Petraitis V, Walsh TJ. Combination therapy for the treatment of pulmonary mold infections[J]. Expert Rev Respir Med, 2017, 11(6): 481-489.
|
| 79 |
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837.
|
| 80 |
Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)[J]. J Antimicrob Chemother, 2019, 74(11): 3315-3327.
|
| 81 |
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653.
|
| 82 |
Powell C, Puig CA, Saddoughi SA, et al. Pulmonary mucormycosis: outcomes by treatment modality and underlying comorbidity[J]. Ann Thorac Surg, 2026, 122(2): 311-319.
|
| 83 |
Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper[J]. Intensive Care Med, 2020, 46(6): 1127-1153.
|
| 84 |
Roberts JA, Sime FB, Lipman J, et al. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study[J]. Intensive Care Med, 2025, 51(2): 302-317.
|
| 85 |
Roger C. Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: a narrative review[J]. J Intensive Med, 2024, 4(3): 287-298.
|
| 86 |
Hanai Y, Hamada Y, Kimura T, et al. Favorable effects of voriconazole trough concentrations exceeding 1 μg/ml on treatment success and all-cause mortality: a systematic review and meta-analysis[J]. J Fungi (Basel), 2021, 7(4): 306.
|
| 87 |
Sanz-Codina M, Bozkir HÖ, Jorda A, et al. Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Microbiol Infect, 2023, 29(7): 845-857.
|
| 88 |
McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium[J]. Pharmacotherapy, 2023, 43(10): 1043-1050.
|
| 89 |
Chastain DB, Anderson DT, Eudy J, et al. Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation[J]. J Antimicrob Chemother, 2026, 81(3): dkag055.
|